Blood-based biomarkers: diagnostic value in brain tumors (focus on gliomas)

Yuting Yang; Fei Hu; Song Wu; Zhangliang Huang; Kun Wei; Yuan Ma; Qing Ou-Yang

doi:10.3389/fneur.2023.1297835

Blood-based biomarkers: diagnostic value in brain tumors (focus on gliomas)

Front Neurol. 2023 Oct 23:14:1297835. doi: 10.3389/fneur.2023.1297835. eCollection 2023.

Authors

Yuting Yang^{1

2}, Fei Hu², Song Wu², Zhangliang Huang^{1

2}, Kun Wei², Yuan Ma^#^{1

2}, Qing Ou-Yang^#²

Affiliations

¹ Institute of Biomedical Engineering, College of Medicine, Southwest Jiaotong University, Chengdu, Sichuan, China.
² Department of Neurosurgery, Affiliated Hospital of Southwest Jiaotong University, The General Hospital of Western Theater Command, Chengdu, Sichuan, China.

^# Contributed equally.

Abstract

Background: Brain tumors, especially gliomas, are known for high lethality. It is currently understood that the correlations of tumors with coagulation and inflammation have been gradually revealed.

Objective: This study aimed to explore the potential value of several reported peripheral blood parameters as comprehensively as possible, with preoperative diagnosis and identification of brain tumors (focus on gliomas).

Methods: Patients with central nervous system tumors (craniopharyngioma, ependymoma, spinal meningioma, acoustic neuroma, brain metastases, meningioma, and glioma) or primary trigeminal neuralgia admitted to our hospital were retrospectively analyzed. The results of the routine coagulation factor test, serum albumin test, and blood cell test in peripheral blood were recorded for each group of patients on admission. Neutrophil-lymphocyte ratio (NLR), derived NLR (dNLR), platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), prognostic nutritional index (PNI), the systemic immune-inflammation index (SII), pan-immune-inflammation value (PIV), and their pairings were calculated. Their ability to identify brain tumors and their correlation with glioma grade were analyzed.

Results: A total of 698 patients were included in this retrospective case-control study. Glioma patients had higher NLR, SII, and PIV but lower LMR. The NLR in the brain metastasis group was lower than that in the control, meningioma, and acoustic neuroma groups, but the SII and PIV were higher than those in the ependymoma group. Fibrinogen, white blood cell count, neutrophil count, NLR, SII, and PIV in the GBM group were higher than those in the control group. In all comparisons, NLR and NLR + dNLR showed the greatest accuracy, with areas under the curve (AUCs) of 0.7490 (0.6482-0.8498) and 0.7481 (0.6457-0.8505), respectively. PIV, dNLR + PIV, and LMR + PIV ranked second, with AUCs of 0.7200 (0.6551-0.7849), 0.7200 (0.6526-0.7874), 0.7204 (0.6530-0.7878) and 0.7206 (0.6536-0.7875), respectively.

Conclusion: NLR, PIV, and their combinations show high sensitivity and specificity in the diagnosis of brain tumors, especially gliomas. Overall, our results provide evidence for these convenient and reliable peripheral blood markers.

Keywords: brain tumors; diagnostic indicator; glioma; neutrophil–lymphocyte ratio; pan-immune-inflammation value.

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The present study was supported by grants from the Research Project of the General Hospital of Western Theater Command (2021–XZYG–A13 and 2021–XZYG–C37) and the Spark Talent program to QO-Y of General Hospital of the Western Theater Command.